Bortezomib

Related products

• 

  Multiple myeloma

  Pomamide

  【Product name】Pomalyst

  [English common name]Pomalidomide

  [Chinese common name]Pomamide

  [English name]

  [Chinese other name]

  [Indications] for the treatment of other drugs are invalidMultiple myeloma.

  [Usage and Dosage] 4 mg, repeated 28 days per day in the day until 1 to 21 of the disease progression. Please refer to the dose of dexamethasone.

  [Storage] The drug does not require any special storage conditions.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Multiple myeloma , Lymphoma

  Lenalidomide

  【Product name】Revlimid

  [English common name]Lenalidomide

  [Chinese common name]Lenalidomide

  [English name]Lenalidomide

  [Chinese other name]Laminamide

  [Indications] This product is combined with dexamethasone to treat at least one therapy.Multiple myelomaAdult patient.

  【Dosage】
  Treatment medication must be initiated and provided under the supervision of a physician with multiple myeloma treatment experience.
  If the patient's absolute neutrophil count (ANC) is <1.0×109/L, or the patient's platelet count is <50×109/L, and the proportion of plasma cells in the bone marrow is less than 50%, or the patient's platelets Counting <30×109/L, and the ratio of plasma cells to nucleated cells in the bone marrow is >50%, then the treatment of this product should not be started.
  Recommended dose
  The recommended starting dose for this product is 25mg. On the 1st to 21st days of each repeated 28-day cycle, 25 mg of this product was orally administered daily until the disease progressed. The recommended dose of dexamethasone is oral administration of 40 mg of dexamethasone on days 1, 8, 15, and 22 of the 28-day treatment cycle.

  [Storage] Store at 20 ° C – 25 ° C (68 ° F – 77 ° F); allow for offset 15 ° C – 30 ° C (59 ° F – 86 ° F).

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Multiple myeloma

  Zoledronic acid

  【Product name】Zoledronic, RECLAST, ZOMETA

  [English common name]Zoledronic

  [Chinese common name]Zoledronic acid

  [English name]

  [Chinese other name]

  [Indications] in combination with standard anti-tumor drug therapy for the treatment of patients with solid tumor bone metastases andMultiple myelomaThe patient's bone damage. It is used to treat hypercalcemia (HCM) caused by malignant tumors.

  [Usage and Dosage] This product should not be used in combination with an infusion solution containing calcium or other divalent cations (such as lactated Ringer's solution). A single intravenous infusion should be performed using an infusion tube separate from other drugs.
  Adult and elderly
  The recommended dose is 4 mg. Dilute with 100 ml of 0.9% sodium chloride or 5% dextrose solution for an intravenous infusion of not less than 15 minutes (see [Precautions]).
  For patients with HCM (albumin-corrected serum calcium ≥ 3.0 mmol/l or 12 mg/dl), a single infusion should be accepted. Albumin-corrected serum calcium (mg/dL) = patient serum calcium (mg/dL) + 0.8 x [median serum albumin (g/L) - patient serum albumin (g/L)].
  There is limited experience with re-treatment of hypercalcemia. Re-treatment must be at least 7-10 days apart from the previous one, and serum creatinine levels should be monitored before treatment.
  The hydration status of the patient must be tested prior to administration and should be administered according to the clinical condition of the patient.
  For patients with bone metastases and multiple myeloma, this product should be given every 3-4 weeks. In addition, patients should take 500 mg of calcium and 400 IU of vitamin D daily.
  Renal insufficiency
  HCM
  For patients with HCM with severe renal impairment, the risk-benefit ratio needs to be assessed before considering the use of this product for treatment. In previous clinical trials, patients with serum creatinine >400 umol/l or >4.5 mg/dl were not enrolled. HCM patients with serum creatinine <400umol/l or <4.5mg/dl do not need to adjust the dose.
  Patient who has developed bone metastasis
  For patients with multiple myeloma and solid tumors that have undergone bone metastases, serum creatinine and creatinine clearance (CrCl) are measured at the start of treatment with this product. The CrCl value was calculated from the serum creatinine concentration value using the Cockcroft-Gault formula. Before using Zetai drugs for treatment, if the patient has developed severe renal insufficiency symptoms (CrCl<30ml/min), it is recommended to give Zetai drugs according to the following dosages (see [Precautions]): CrCl>60ml /min: 4.0 mg; CrCl 50-60 ml/min: 3.5 mg; CrCl40-49 ml/min: 3.3 mg; CrCl30-39 ml/min: 3.0 mg.
  This dose was calculated based on the assumed AUS target value of 0.66 (mgxhr/l) (CrCl = 75 ml/min). The purpose of using this dose reduction method is to achieve the same AUC value for patients with renal insufficiency as patients with creatinine clearance of 75 ml/min.
  After starting the medication, the serum creatinine concentration of the patient is measured before each administration of the product. Once the patient's renal function is found to be deteriorating, medication withdrawal is required. In clinical trials, the definition of deterioration of renal function is this:
  Serum creatinine concentrations increased from baseline normal (dl) to ≥0.5 mg/dl; and serum creatinine concentrations increased from baseline outliers (>1.4 mg/dl) to >1.0 mg/dl.
  In clinical studies, treatment of this product is continued only when creatinine levels are restored to within 10% of the baseline value (see [Precautions]). The dose of drug used to re-use Zetai should be the dose of the drug used in the previous treatment interruption.
  Hepatic insufficiency
  Because of the limited clinical data on patients with severe hepatic insufficiency, there are no specific recommendations for such patients.
  Child medication
  The safety and effectiveness of this product for children and adolescents has not yet been established.

  [Storage]Store below 30 °C.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Multiple myeloma

  A-protease inhibitor

  【Product name】Zemaira

  [English common name]a lpha1-proteinase

  [Chinese common name]A-protease inhibitor

  [English name]

  [Chinese other name]

  [Indications] It is used to alleviate lung damage in patients with severe diseases.

  [Usage and Dosage] The recommended dose is 60 mg per kg of body weight, once a week. The infusion should last for about 15 minutes.

  [Storage] ZemairaTM remains stable for the life of the label when stored at temperatures up to 25 ° C (77 ° F). Avoid freezing, otherwise the container of the thinner may be damaged.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.